Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
Identifieur interne : 000562 ( PubMed/Curation ); précédent : 000561; suivant : 000563Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
Auteurs : Xavier Duval [France] ; Adrian Caplanusi ; Henri Laurichesse ; Dominique Deplanque ; Pierre Loulergue ; Tejaswini Vaman ; Odile Launay ; Paul GillardSource :
- BMC infectious diseases [ 1471-2334 ] ; 2012.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Adjuvants immunologiques (effets indésirables), Adolescent, Adulte, Adulte d'âge moyen, Anticorps antiviraux (sang), Calendrier vaccinal, Facteurs de l'âge, Facteurs temps, Femelle, Grippe humaine (), Humains, Jeune adulte, Mâle, Sous-type H1N1 du virus de la grippe A (immunologie), Tests d'inhibition de l'hémagglutination, Vaccination (), Vaccination (effets indésirables), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins antigrippaux.
- effets indésirables : Adjuvants immunologiques, Vaccination, Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- sang : Anticorps antiviraux.
- Adolescent, Adulte, Adulte d'âge moyen, Calendrier vaccinal, Facteurs de l'âge, Facteurs temps, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Tests d'inhibition de l'hémagglutination, Vaccination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (adverse effects), Adolescent, Adult, Age Factors, Antibodies, Viral (blood), Female, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Male, Middle Aged, Time Factors, Vaccination (adverse effects), Vaccination (methods), Young Adult.
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines.
- chemical , adverse effects : Adjuvants, Immunologic, Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- adverse effects : Vaccination.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines.
- methods : Vaccination.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Age Factors, Female, Hemagglutination Inhibition Tests, Humans, Immunization Schedule, Male, Middle Aged, Time Factors, Young Adult.
Abstract
Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose schedule at intervals of 21 days or 6 months in both young and elderly adults.
DOI: 10.1186/1471-2334-12-162
PubMed: 22824474
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000564
Links to Exploration step
pubmed:22824474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.</title><author><name sortKey="Duval, Xavier" sort="Duval, Xavier" uniqKey="Duval X" first="Xavier" last="Duval">Xavier Duval</name><affiliation wicri:level="1"><nlm:affiliation>Université Paris Diderot, Sorbonne Paris Cité, Paris, UMR 738, France. xavier.duval@bch.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Diderot, Sorbonne Paris Cité, Paris, UMR 738</wicri:regionArea></affiliation></author><author><name sortKey="Caplanusi, Adrian" sort="Caplanusi, Adrian" uniqKey="Caplanusi A" first="Adrian" last="Caplanusi">Adrian Caplanusi</name></author><author><name sortKey="Laurichesse, Henri" sort="Laurichesse, Henri" uniqKey="Laurichesse H" first="Henri" last="Laurichesse">Henri Laurichesse</name></author><author><name sortKey="Deplanque, Dominique" sort="Deplanque, Dominique" uniqKey="Deplanque D" first="Dominique" last="Deplanque">Dominique Deplanque</name></author><author><name sortKey="Loulergue, Pierre" sort="Loulergue, Pierre" uniqKey="Loulergue P" first="Pierre" last="Loulergue">Pierre Loulergue</name></author><author><name sortKey="Vaman, Tejaswini" sort="Vaman, Tejaswini" uniqKey="Vaman T" first="Tejaswini" last="Vaman">Tejaswini Vaman</name></author><author><name sortKey="Launay, Odile" sort="Launay, Odile" uniqKey="Launay O" first="Odile" last="Launay">Odile Launay</name></author><author><name sortKey="Gillard, Paul" sort="Gillard, Paul" uniqKey="Gillard P" first="Paul" last="Gillard">Paul Gillard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22824474</idno><idno type="pmid">22824474</idno><idno type="doi">10.1186/1471-2334-12-162</idno><idno type="wicri:Area/PubMed/Corpus">000564</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000564</idno><idno type="wicri:Area/PubMed/Curation">000562</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000562</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.</title><author><name sortKey="Duval, Xavier" sort="Duval, Xavier" uniqKey="Duval X" first="Xavier" last="Duval">Xavier Duval</name><affiliation wicri:level="1"><nlm:affiliation>Université Paris Diderot, Sorbonne Paris Cité, Paris, UMR 738, France. xavier.duval@bch.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Diderot, Sorbonne Paris Cité, Paris, UMR 738</wicri:regionArea></affiliation></author><author><name sortKey="Caplanusi, Adrian" sort="Caplanusi, Adrian" uniqKey="Caplanusi A" first="Adrian" last="Caplanusi">Adrian Caplanusi</name></author><author><name sortKey="Laurichesse, Henri" sort="Laurichesse, Henri" uniqKey="Laurichesse H" first="Henri" last="Laurichesse">Henri Laurichesse</name></author><author><name sortKey="Deplanque, Dominique" sort="Deplanque, Dominique" uniqKey="Deplanque D" first="Dominique" last="Deplanque">Dominique Deplanque</name></author><author><name sortKey="Loulergue, Pierre" sort="Loulergue, Pierre" uniqKey="Loulergue P" first="Pierre" last="Loulergue">Pierre Loulergue</name></author><author><name sortKey="Vaman, Tejaswini" sort="Vaman, Tejaswini" uniqKey="Vaman T" first="Tejaswini" last="Vaman">Tejaswini Vaman</name></author><author><name sortKey="Launay, Odile" sort="Launay, Odile" uniqKey="Launay O" first="Odile" last="Launay">Odile Launay</name></author><author><name sortKey="Gillard, Paul" sort="Gillard, Paul" uniqKey="Gillard P" first="Paul" last="Gillard">Paul Gillard</name></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adjuvants, Immunologic (adverse effects)</term><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Antibodies, Viral (blood)</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunization Schedule</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Vaccination (adverse effects)</term><term>Vaccination (methods)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Adjuvants immunologiques (effets indésirables)</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (sang)</term><term>Calendrier vaccinal</term><term>Facteurs de l'âge</term><term>Facteurs temps</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination ()</term><term>Vaccination (effets indésirables)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier vaccinal</term><term>Facteurs de l'âge</term><term>Facteurs temps</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose schedule at intervals of 21 days or 6 months in both young and elderly adults.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22824474</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2012</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.</ArticleTitle><Pagination><MedlinePgn>162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2334-12-162</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose schedule at intervals of 21 days or 6 months in both young and elderly adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this open-label randomized trial, healthy adults aged 18-60 years (N = 163) and >60 years (N = 143) received AS03A-adjuvanted A/California/7/2009 H1N1 vaccine containing 1.9 μg HA on Day 0. A second dose was given on Day 21 (n = 177) or Day 182 (n = 106). Haemagglutination-inhibition (HI) antibody responses were analyzed on Days 0, 21, 42, 182, 364 and additionally on Day 203 for subjects vaccinated on Day 182. Solicited and unsolicited adverse events were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The HI antibody response in both age strata 21 days after the first dose met and exceeded all regulatory acceptance criteria although the results suggested a lower response in the older age stratum (geometric mean titres [GMTs] for HI antibodies of 420.5 for subjects aged 18-60 years and 174.4 for those >60 years). A second dose of AS03A adjuvanted A/H1N1/2009 vaccine induced a further increase in antibody titres and the response was similar whether the second dose was administered at 21 days (GMTs of 771.8 for 18-60 years and 400.9 for >60 years) or 6 months (GMTs of 708.3 for 18-60 years and 512.1 for >60 years) following the first dose. Seroprotection rates remained high at 6 months after one dose or two doses while at 12 months rates tended to be higher for the 6 month interval schedule (93.3% for 18-60 years and 80.4% for >60 years) than the 21 day schedule (82.3% for 18-60 years and 50.0% for >60 years). Reactogenicity/safety profiles were similar for both schedules, there was no evidence of an increase in reactogenicity following the second dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results indicate that flexibility in the dosing interval for AS03A adjuvanted vaccine may be possible. Such flexibility could help to reduce the logistic stress on delivery of pandemic vaccination programmes.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, NCT00975884.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duval</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Université Paris Diderot, Sorbonne Paris Cité, Paris, UMR 738, France. xavier.duval@bch.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caplanusi</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Laurichesse</LastName><ForeName>Henri</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Deplanque</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Loulergue</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Vaman</LastName><ForeName>Tejaswini</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Launay</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Gillard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00975884</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22824474</ArticleId><ArticleId IdType="pii">1471-2334-12-162</ArticleId><ArticleId IdType="doi">10.1186/1471-2334-12-162</ArticleId><ArticleId IdType="pmc">PMC3522029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19644442</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2424-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19745215</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2405-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19745216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 2;375(9708):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20018365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 2;375(9708):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20018367</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Feb 17;28(7):1740-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20034605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2010 Aug 1;185(3):1642-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20585035</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Sep 15;51(6):668-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2010 Oct;16(10):1515-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20875275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Apr 15;203(8):1054-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21450995</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2011 May;18(5):835-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21450978</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 Mar 1;205(5):733-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22315336</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7(1):55-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22405557</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 23;27(45):6284-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19856521</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Mar 15;172(6):3437-46</Citation><ArticleIdList><ArticleId IdType="pubmed">15004143</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Feb 20;24(8):1159-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16213065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId></ArticleIdList></Reference><Reference><Citation>J Public Health Policy. 2007;28(3):322-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17717543</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2007 Oct;6(5):699-710</Citation><ArticleIdList><ArticleId IdType="pubmed">17931151</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008;3(1):e1401</Citation><ArticleIdList><ArticleId IdType="pubmed">18167560</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008;3(2):e1665</Citation><ArticleIdList><ArticleId IdType="pubmed">18301743</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 May 2;26(19):2378-88</Citation><ArticleIdList><ArticleId IdType="pubmed">18407382</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Sep 1;198(5):632-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18652548</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Dec 9;27(52):7428-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19683087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22824474
|texte= Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22824474" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |